Aesculap's 1995 sales rise 3.8%
This article was originally published in Clinica
Despite difficult business conditions, Aesculap achieved a 3.8% rise in sales to DM 544.8 million ($390 million) during fiscal 1995 (ended September 30th). In the German company's home market, turnover increased 7.2% to DM 186.5 million, while Asia showed very healthy growth, up 11.2% to DM 81.5 million. Exchange rate effects caused US sales to fall 5.2% in Deutschmark terms, although expressed in dollars they grew 7.4%.
You may also be interested in...
The International Generic and Biosimilar Medicines Association has urged the World Intellectual Property Organization to withdraw its support for a global database of pharmaceutical patent information. The Pat-INFORMED database – which is comprised of intellectual-property information provided by originators – contains unverified data and lacks appropriate safeguards, the IGBA contends.
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.